The antidiabetic effect of MSCs is not impaired by insulin prophylaxis and is not improved by a second dose of cells.
about
Concise review: pancreas regeneration: recent advances and perspectivesβ-Cell regeneration mediated by human bone marrow mesenchymal stem cells.Recipient Glycemic Micro-environments Govern Therapeutic Effects of Mesenchymal Stem Cell Infusion on OsteopeniaOmental adipose tissue is a more suitable source of canine Mesenchymal stem cellsCould cancer and infection be adverse effects of mesenchymal stromal cell therapy?Metabolic and pancreatic effects of bone marrow mesenchymal stem cells transplantation in mice fed high-fat diet.Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats: identification of a novel role in improving insulin sensitivity.Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes.Infusion with Human Bone Marrow-derived Mesenchymal Stem Cells Improves β-cell Function in Patients and Non-obese Mice with Severe DiabetesBone marrow stem cell as a potential treatment for diabetes.Administration of multipotent mesenchymal stromal cells restores liver regeneration and improves liver function in obese mice with hepatic steatosis after partial hepatectomy.Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats.The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment.Bone-Marrow-Derived Mesenchymal Stromal Cells (MSC) from Diabetic and Nondiabetic Rats Have Similar Therapeutic Potentials.
P2860
Q27013646-80565B80-31D5-4492-9D5B-3F6A3D542349Q31081664-C5E8D8DD-ED7A-4953-8915-F1835CEA1D00Q33588206-B00DEFCE-A3F3-4074-98B1-2FE933B47F47Q33781303-7EB51CEA-5016-4D59-86A3-E42100D3E5C2Q35205677-6B3A052D-5679-4B7B-B9A2-E4B53F9D4F24Q35552255-E0EAABF5-B59E-4CC1-BD63-B07B81A570A8Q35976735-D19D0772-578C-4EBF-BAC7-FD491BA3F368Q37204124-33E57EB4-B898-4F7A-954D-459D74933149Q37460214-939C0824-605C-462F-8446-0F0DFB1E45DEQ38106720-B30484D9-4AAF-4F3A-B6FE-E4AE1332BC72Q42327233-9D5F7345-216D-4048-93E4-DF29A65CA836Q43648419-2562A1B2-CE81-4988-93D4-F396E9A12611Q47695204-74B99843-3073-488F-AF76-7E2A73103413Q49825790-48AD2ACF-5738-4D06-84FE-D54D79C86CC6
P2860
The antidiabetic effect of MSCs is not impaired by insulin prophylaxis and is not improved by a second dose of cells.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The antidiabetic effect of MSC ...... ved by a second dose of cells.
@ast
The antidiabetic effect of MSC ...... ved by a second dose of cells.
@en
type
label
The antidiabetic effect of MSC ...... ved by a second dose of cells.
@ast
The antidiabetic effect of MSC ...... ved by a second dose of cells.
@en
prefLabel
The antidiabetic effect of MSC ...... ved by a second dose of cells.
@ast
The antidiabetic effect of MSC ...... ved by a second dose of cells.
@en
P2093
P2860
P1433
P1476
The antidiabetic effect of MSC ...... ved by a second dose of cells.
@en
P2093
Fernando Ezquer
Marcelo Ezquer
Valeska Simon
P2860
P304
P356
10.1371/JOURNAL.PONE.0016566
P407
P577
2011-01-27T00:00:00Z